Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Biohaven to Proceed with Intranasal Vazegepant Trial for COVID-19 Lung Inflammation

americanpharmaceuticalreviewApril 14, 2020

Tag: Biohaven Pharmaceutical , COVID-19 , lung injury , Vazegepant

PharmaSources Customer Service